![](https://endpts.com/wp-content/uploads/2021/06/Joel-Perlmutter-1-scaled.jpg)
Joel Perlmutter
Adcomm member who warned about risk of approving Biogen's aducanumab has resigned following historic OK — reports
One of the 11 experts the FDA had convened to discuss Biogen’s aducanumab — before overriding their recommendation and approving the Alzheimer’s drug — has resigned from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.